Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2000

View Archived Issues

Antisoma makes significant progress in product pipeline

Thalidomide improves tolerability of irinotecan in colorectal cancer patients

Genta presents clinical trial update for Genasense

Genzyme General's BLA for Fabry's disease accepted by FDA

Study of pulmonary delivery of patented respiratory drug completed at Sheffield

Antex Pharma licenses new peptides to treat lung diseases

IntraDose receives orphan drug status for melanoma indication

Levaquin tablets/injection approved for new indication in U.S.

Synaptic broadens access to drug design technology

Pierre Fabre and bioMerieux to merge

Roche and BMS form alliance to study Herceptin/Taxol anticancer combination

Italian researchers present newly discovered 5alpha-reductase isoform 1-selective inhibitors

RP-60556A, a new topical antibacterial agent for Gram-positive infections

Baxter and Peptide Therapeutics enter collaboration for vaccine development

Fluticasone more effective than montelukast in asthma control

Korean carbapenem compares favorably to meropenem regarding antibacterial activity, safety

New inhibitors of beta-amyloid fibril formation reported by Novartis

Two recently issued patents cover Pfizer's new PTK inhibitors

Neurotrophic agents with novel profile designed at Schering AG

Shionogi presents new MMP inhibitors with cyclic structure

Factor Xa inhibitors synthesized and tested at AstraZeneca

Preparation and use of new compounds inhibiting fat accumulation described by Sumitomo

Novel calcilytic compounds useful for bone disorders

Spectrum of new ketolide includes susceptible and resistant respiratory tract pathogens

Chiron takes first step towards merger with PathoGenesis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...